Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sectra ABCHIX:SECTBS 98 3-Year EBITDA Growth Rate is 14.10% as of Apr. 2026, which is 18% above its 10-year median of 11.95. GuruFocus rates CHIX:SECTBS with a GF Score™ of 98/100 and a GF Value™ of kr311.75 (Modestly Undervalued). Among 691 Medical Devices & Instruments companies, Sectra AB ranks better than 57.6% on this metric.
During the past 12 months, Sectra AB's average EBITDA Per Share Growth Rate was 1.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sectra AB was 20.80% per year. The lowest was -7.50% per year. And the median was 11.95% per year.
Sectra AB (CHIX:SECTBs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sectra AB 3-Year EBITDA Growth Rate Related Terms
CHIX:SECTBS vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Sectra AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sectra AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sectra AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sectra AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.10% mean?
Sectra AB (CHIX:SECTBS) has a 3-Year EBITDA Growth Rate of 14.10% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sectra AB and its competitors. This is 18% above median its historical median of 11.95. According to the industry distribution chart, Sectra AB ranks #293 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 42.4%.
Is Sectra AB's 3-Year EBITDA Growth Rate too high?
Sectra AB's current 3-Year EBITDA Growth Rate of 14.10% is 18% above median its 10-year median of 11.95. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Sectra AB's value of 14.10% is 74.1% above this industry median. Based on the distribution chart, Sectra AB ranks #293 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sectra AB has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sectra AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sectra AB ranks #293 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Sectra AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Sectra AB's value of 14.10% is 74.1% above this benchmark. While the company's 10-year median is 11.95 vs. the industry median of 8.10, Sectra AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sectra AB's current 3-Year EBITDA Growth Rate of 14.10% is 74.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sectra AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sectra AB's current 3-Year EBITDA Growth Rate is 14.10%, which is 18% above median its own 10-year median of 11.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sectra AB stock overvalued right now?
Based on GuruFocus' analysis, Sectra AB (CHIX:SECTBS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr311.75, compared to a current price of kr277.30 — trading 11.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.10%, which is 18% above median its 10-year median of 11.95 and 74.1% above the Medical Devices & Instruments industry median of 8.10. Sectra AB's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sectra AB (CHIX:SECTBS), the current 3-Year EBITDA Growth Rate is 14.10% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sectra AB (CHIX:SECTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Sectra AB stock appears to be undervalued.
The current stock price of kr277.30 is trading 11.1% below its estimated GF Value™ of kr311.75.
GuruFocus considers Sectra AB to be Modestly Undervalued.
Key valuation signals for CHIX:SECTBS:
3-Year EBITDA Growth Rate: 14.10% (18% above median its 10-year median of 11.95)
GF Value™: kr311.75 vs. price of kr277.30 (11.1% below fair value)
Industry Position: 74.1% above the Medical Devices & Instruments median (#293 of 691)
No single metric tells the full story. See the CHIX:SECTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sectra AB develops IT solutions and services for storing, viewing, and working with medical images. The operating business segments are Imaging IT Solutions, Secure Communications, Business Innovation, and Other Operations. It generates maximum revenue from the Imaging IT Solutions segment. The company also offers maintenance in the form of support, system monitoring, and consulting services related to integration, system design, data migration, and business development. Geographically, it derives a majority of its revenue from the United States, followed by Sweden, the United Kingdom, the Netherlands, the Rest of Europe, and the Rest of the world.
98GF Score
Get the complete analysis for CHIX:SECTBS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SECTBS has been successfully added to your 
